GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Total Liabilities

IXICO (LSE:IXI) Total Liabilities : £1.53 Mil (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is IXICO Total Liabilities?

IXICO's Total Liabilities for the quarter that ended in Mar. 2024 was £1.53 Mil.

IXICO's quarterly Total Liabilities declined from Mar. 2023 (£1.90 Mil) to Sep. 2023 (£1.56 Mil) and declined from Sep. 2023 (£1.56 Mil) to Mar. 2024 (£1.53 Mil).

IXICO's annual Total Liabilities declined from Sep. 2021 (£2.78 Mil) to Sep. 2022 (£2.16 Mil) and declined from Sep. 2022 (£2.16 Mil) to Sep. 2023 (£1.56 Mil).


IXICO Total Liabilities Historical Data

The historical data trend for IXICO's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Total Liabilities Chart

IXICO Annual Data
Trend Sep13 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.78 2.79 2.78 2.16 1.56

IXICO Semi-Annual Data
Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.04 2.16 1.90 1.56 1.53

IXICO Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IXICO's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.281+(0.275+0.0020000000000001
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.56

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=12.99-11.432
=1.56

IXICO's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.324+(0.208+-2.7755575615629E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.53

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=11.57-10.038
=1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IXICO Total Liabilities Related Terms

Thank you for viewing the detailed overview of IXICO's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


IXICO (LSE:IXI) Business Description

Traded in Other Exchanges
Address
15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN
IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines